A Lancet meta-analysis reveals a substantial gap between how cannabis is currently used clinically and the proven evidence for treating major disorders like depression or PTSD. The underlying conflict centers on whether temporary symptom relief constitutes adequate medical proof, or if the science itself is compromised.

Pro-Cannabis voices, like Infamousblt, argue that the science is flawed, stating cannabis simply helps 'take the edge off'—a function comparable to existing medications. Skeptics, represented by village604, argue that anecdote cannot counter science, while others, like SapphireSphinx, point fingers at prohibition and vested interests maintaining the pharmaceutical status quo. Conversely, some acknowledge the need for caution, like village604, while others point to alternative paths, such as mar_k suggesting psychedelics alongside cannabis.

The dominant takeaway is that the conversation is split between data interpretation and distrust of the system. While science calls for large, unbiased, long-term studies (as noted by TronBronson), a significant current undercurrent suggests the entire pharmaceutical paradigm is driven by profit, possibly suppressing effective alternatives.